EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock closed at $17.50 on 4/18/24 after a major decline of -16.4%. Moreover, this decline was accompanied by exceptionally high trading volume at 451% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -19.4% during the last week.
Current PriceTarget Research Rating
EYPT is expected to continue to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
EyePoint Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. EyePoint Pharmaceuticals has a very low Appreciation Score of 13 but a very high Power Rating of 93, leading to the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment